## nature portfolio

Corresponding author(s):	R.J. Verheijden
Last updated by author(s):	Apr 6, 2023

## **Reporting Summary**

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

_				
C-	トつ	11	ct	ics
			<b>``</b>	11 >

FOI a	II Sta	atisticai ana	nyses, commitment the following items are present in the figure regend, table legend, main text, or Methods section.			
n/a	Con	ıfirmed				
	$\square$ The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement					
$\boxtimes$		A statemer	nt on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly			
			cal test(s) used AND whether they are one- or two-sided on tests should be described solely by name; describe more complex techniques in the Methods section.			
$\boxtimes$	A description of all covariates tested					
$\boxtimes$	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons					
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)					
	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i> ) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>					
$\boxtimes$	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings					
$\boxtimes$	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes					
	$\square$ Estimates of effect sizes (e.g. Cohen's $d$ , Pearson's $r$ ), indicating how they were calculated					
Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.						
Software and code						
Policy information about <u>availability of computer code</u>						
Dat	Data collection PubMed, MedRxiv, BioRxiv, and clinicaltrials.gov were used to collect relevant literature.					

The code to create Figure 2 and 3 is available via: https://github.com/rjverheijden/ICI immunosuppression review 2023

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

## Data

Data analysis

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

Data referenced in this review can be accessed by following resources numbered in the Reference section.

Human resea	arch part	icipants		
Policy information a	about <u>studies i</u>	involving human research participants and Sex and Gender in Research.		
Reporting on sex and gender N/A review article		N/A review article		
Population charac	cteristics	N/A review article		
Recruitment N/A review article		N/A review article		
Ethics oversight		N/A review article		
Note that full informa	tion on the app	roval of the study protocol must also be provided in the manuscript.		
Field-spe	cific re	eporting		
Please select the on	ne below that	is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.		
Life sciences		Behavioural & social sciences		
For a reference copy of th	he document with	all sections, see <a href="nature.com/documents/nr-reporting-summary-flat.pdf">nature.com/documents/nr-reporting-summary-flat.pdf</a>		
Life scien	ices st	udy design		
All studies must disc	close on these	points even when the disclosure is negative.		
Sample size	N/A review art	icle		
Data exclusions	N/A review art	icle		
Replication	N/A review art	icle		
Randomization	N/A review art	icle		
Blinding	N/A review art	icle		
_				
Reporting	g for s	pecific materials, systems and methods		
		about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.		
,				
Materials & experimental systems Methods				
Antibodies ChIP-seq				
Eukaryotic cell lines    Flow cytometry				
∑   Palaeontolo	Palaeontology and archaeology MRI-based neuroimaging			

Palaeontology and archaeology Animals and other organisms

Dual use research of concern

Clinical data